CL2010001539A1 - Antibody or fragment thereof, specific for a desired antigen comprising light chain cdr of a lagomorph and a human variable heavy chain framework; said framework, nucleic acid encoding it, vector; host cell; composition that includes it; and method to humanize a rabbit antibody. - Google Patents

Antibody or fragment thereof, specific for a desired antigen comprising light chain cdr of a lagomorph and a human variable heavy chain framework; said framework, nucleic acid encoding it, vector; host cell; composition that includes it; and method to humanize a rabbit antibody.

Info

Publication number
CL2010001539A1
CL2010001539A1 CL2010001539A CL2010001539A CL2010001539A1 CL 2010001539 A1 CL2010001539 A1 CL 2010001539A1 CL 2010001539 A CL2010001539 A CL 2010001539A CL 2010001539 A CL2010001539 A CL 2010001539A CL 2010001539 A1 CL2010001539 A1 CL 2010001539A1
Authority
CL
Chile
Prior art keywords
framework
antibody
lagomorph
humanize
vector
Prior art date
Application number
CL2010001539A
Other languages
Spanish (es)
Inventor
Leonardo Urech David Borras
Original Assignee
Esbatech And Alcon Biomedical Reserch Unit Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech And Alcon Biomedical Reserch Unit Llc filed Critical Esbatech And Alcon Biomedical Reserch Unit Llc
Publication of CL2010001539A1 publication Critical patent/CL2010001539A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Abstract

Inmunoenlazador específico para un antígeno deseado que comprende CDRS de cadena liviana de un lagomorfo y un armazón de cadena pesada variable humana; dicho armazón; ácido nucleico que lo codifica; vector; célula huésped; composición que lo comprende; y método para humanizar un inmunoenlazador de conejo.Specific immuno linker for a desired antigen comprising light chain CDRS of a lagomorph and a human variable heavy chain framework; said framework; nucleic acid encoding it; vector; host cell; composition that includes it; and method to humanize a rabbit immuno linker.

CL2010001539A 2008-06-25 2010-12-23 Antibody or fragment thereof, specific for a desired antigen comprising light chain cdr of a lagomorph and a human variable heavy chain framework; said framework, nucleic acid encoding it, vector; host cell; composition that includes it; and method to humanize a rabbit antibody. CL2010001539A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7569708P 2008-06-25 2008-06-25
US7569208P 2008-06-25 2008-06-25
US15504109P 2009-02-24 2009-02-24
US15510509P 2009-02-24 2009-02-24
CH8322009 2009-06-02

Publications (1)

Publication Number Publication Date
CL2010001539A1 true CL2010001539A1 (en) 2012-02-03

Family

ID=53532693

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001539A CL2010001539A1 (en) 2008-06-25 2010-12-23 Antibody or fragment thereof, specific for a desired antigen comprising light chain cdr of a lagomorph and a human variable heavy chain framework; said framework, nucleic acid encoding it, vector; host cell; composition that includes it; and method to humanize a rabbit antibody.

Country Status (9)

Country Link
JP (5) JP2015120746A (en)
KR (2) KR102284435B1 (en)
CL (1) CL2010001539A1 (en)
ES (1) ES2771150T3 (en)
HU (1) HUE047678T2 (en)
PH (2) PH12013502219A1 (en)
PT (2) PT2307458T (en)
RU (2) RU2696202C1 (en)
ZA (3) ZA201008592B (en)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253593T1 (en) * 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr IMMUNOGLOBULIN SUPERFAMILY DOMAINS AND FRAGMENTS WITH INCREASED SOLUBILITY
AU2001284703B2 (en) * 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
EP1404353A4 (en) * 2001-04-25 2006-06-14 Paul H Weigel Methods of using a hyaluronan receptor
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
EP1506236B1 (en) * 2002-05-22 2013-01-23 ESBATech - a Novartis Company LLC Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
CA2492524A1 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
CN100415765C (en) * 2003-08-07 2008-09-03 宜康公司 Methods for humanizing rabbit monoclonal antibodies
EP1660534A2 (en) * 2003-08-22 2006-05-31 MedImmune, Inc. Humanization of antibodies
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
US8067547B2 (en) * 2005-06-07 2011-11-29 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting TNFα
BRPI0613382A8 (en) * 2005-06-20 2018-01-02 Genentech Inc isolated antibodies, monoclonal antibody, hybridoma cell, identification method, cell growth inhibition method, therapeutic treatment method, protein presence determination method, tumor presence diagnosis methods
GB0520436D0 (en) * 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
WO2008004834A1 (en) * 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
DK2125894T3 (en) * 2007-03-22 2019-03-18 Biogen Ma Inc BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, SPECIFICALLY BINDING CD154 AND APPLICATIONS THEREOF

Also Published As

Publication number Publication date
JP2016135815A (en) 2016-07-28
RU2696202C1 (en) 2019-07-31
JP2020114260A (en) 2020-07-30
JP6568557B2 (en) 2019-08-28
KR20190091578A (en) 2019-08-06
RU2019119412A (en) 2020-12-21
HUE047678T2 (en) 2020-05-28
KR20210097819A (en) 2021-08-09
JP2019065050A (en) 2019-04-25
KR102284435B1 (en) 2021-08-02
ZA201503267B (en) 2016-07-27
ES2771150T3 (en) 2020-07-06
PH12018501715A1 (en) 2019-08-19
JP6903083B2 (en) 2021-07-14
JP2015120746A (en) 2015-07-02
PT2752428T (en) 2020-02-14
PH12013502219A1 (en) 2016-01-25
PT2307458T (en) 2018-07-18
ZA201308755B (en) 2015-08-26
ZA201008592B (en) 2014-02-26
JP2017190352A (en) 2017-10-19

Similar Documents

Publication Publication Date Title
CL2011002380A1 (en) Multispecific antibody comprising a full length antibody that specifically binds to a first antigen and one or more single chain fab fragments that bind to one or more antigens, nucleic acid encoding it; and pharmaceutical composition that includes it.
CL2023002239A1 (en) b7-h4 antibodies and methods of using them
EA201791961A1 (en) ANTIBODIES SPECIFIC TO CD47 AND PD-L1
PE20180042A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM
CL2012001096A1 (en) Isolated antigen binding protein that binds yl-23, comprising at least both a heavy chain and light chain variable region comprising mutated cdrs; nucleic acid, vector and host cell encoding it; pharmaceutical composition; and its use to treat il-23 associated diseases in a patient.
PE20160553A1 (en) ANTIBODY SPECIFIC ANTAGONIST FOR ALPHA-4-BETA-7 HETERODIMER
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ728749A (en) Anti-pd-l1 antibodies
CL2012002662A1 (en) Bispecific anti-veg bivalent antibodies and a second antigen binding site that specifically binds to human ang-2; pharmaceutical composition comprising said antibody; method of treatment of a patient suffering from cancer; nucleic acid encoding said antibody, expression vector and host cell containing said nucleic acid.
AR095980A1 (en) SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP (FIBROBLASTIC ACTIVATION PROTEIN) AND DR5 (DEATH RECEIVER 5), SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE
EA201591091A1 (en) Antigen-binding proteins for BCMA
AR093984A1 (en) ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
EA201490053A1 (en) ANTIBODIES THAT ARE BIND OX40 AND THEIR APPLICATION
UA106070C2 (en) Antibody that specifically binds to egfr and her3
CL2012000524A1 (en) Humanized antibody that binds to human cdcp1 useful in the treatment of cancer; pharmaceutical composition; nucleic acid, expression vector and host cell comprising it; and method of producing the antibody.
AR094872A1 (en) ANTI-TNF-ANTI-IL-17 BIESPECTIFIC ANTIBODIES
ECSP13012525A (en) ANTIBODIES AGAINST METALOPROTEASA-9 MATRIX.
CR11337A (en) ANTIBODIES THAT JOIN IL-4 AND / OR IL-13 AND ITS USES
MX2018007630A (en) Antibodies to matrix metalloproteinase 9.
CL2011003149A1 (en) Bispecific tetravalent antigen-binding protein comprising a modified heavy chain that specifically binds a first antigen, another heavy chain that binds a second antigen, and four light chains; Preparation method; host cell; pharmaceutical composition; and its use to treat cancer.
CL2013001403A1 (en) Anti-ccl20 monoclonal antibody or a binding fragment thereof; nucleic acid molecule that encodes it; vector; host cell; Method of production; composition that includes it; And its use.
ES2639026T3 (en) Totally human antibodies specific for CADM1
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
EA201491965A1 (en) SLIP PROTEINS TO FACILITATE THE SELECTION OF CELLS INFECTED WITH A RECOMBINANT VIRUS OF OSPOVACCINE WITH THE SPECIFIC IMMUNOGLOBULIN GENE
AR075849A1 (en) MOLECULES OF ANTIBODIES THAT HAVE SPECIFICITY OF UNION BY HUMAN IL-13